Shot in the HAART: vaccine therapy for HIV

ML Robb, JH Kim - The Lancet infectious diseases, 2014 - thelancet.com
ML Robb, JH Kim
The Lancet infectious diseases, 2014thelancet.com
In 1890 The Lancet reported that Robert Koch was starting trials of a therapeutic vaccine for
tuberculosis, noting that “we may be on the verge of a revolution”. 1 A century later, vaccines
for therapy in general or against infectious diseases in particular have not yet achieved
revolutionary status, although the approval of sipuleucel-T for therapeutic vaccination of
metastatic prostate cancer was an important milestone. 2 In The Lancet Infectious Diseases,
Richard Pollard and colleagues3 report that the Vacc-4x HIV Gag conserved peptide …
In 1890 The Lancet reported that Robert Koch was starting trials of a therapeutic vaccine for tuberculosis, noting that “we may be on the verge of a revolution”. 1 A century later, vaccines for therapy in general or against infectious diseases in particular have not yet achieved revolutionary status, although the approval of sipuleucel-T for therapeutic vaccination of metastatic prostate cancer was an important milestone. 2 In The Lancet Infectious Diseases, Richard
Pollard and colleagues3 report that the Vacc-4x HIV Gag conserved peptide vaccine given during combination antiretroviral therapy (cART) was associated with lower setpoint viral load after analytical treatment interruption (ATI) than was placebo. Although there were no differences in primary endpoints of either the proportion of volunteers needing restart of cART or in postATI CD4 cell counts, this study represents one of the few successful randomised trials showing a favourable viral-load effect of therapeutic HIV vaccination.
thelancet.com